Ikonisys Competitors

Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease. To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas. We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures. A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.

PathAI's mission is to improve patient outcomes with AI-powered pathology. Our platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine learning. We are a company of diverse employees with a wide range of backgrounds and experiences. Our world class team is passionate about solving challenging problems and making a huge impact. Our office is located in the heart of Fenway. PathAI was recently voted one of BBJ's Best Places to Work!

As a global leader in precision medicine testing services, we partner with our clients to address the most complex biomarker and bioanalytical challenges and deliver highly customized testing solutions. With facilities located in Canada, United States, Belgium, Australia and China, CellCarta provides the expertise needed locally to support global clinical trials. CellCarta offers access to integrated analytical platforms in immunology (immune monitoring), histopathology, proteomics and genomics, as well as digital pathology/AI and sample management, logistics and kitting services. At CellCarta we are experts at assessing the immune system, whether in the context of oncology, infectious diseases, or autoimmune diseases. With a proven track record in other therapeutic areas as, such as neurological and metabolic disorders, we handle all human biological specimens and deploy relevant technologies to extract valuable information for research and diagnostic applications. We provide assay development and testing services to support a wide variety of translational research, clinical trials, and diagnostic applications. Reflecting our commitment to quality, our sites hold the appropriate accreditations to support your regulatory requirements, including CAP, CLIA, ISO15189, ISO27001 and ISO13485.